New medical evidence indicates that lower limbs amputations may be a “drug-class” side effect for all of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor diabetes drugs which have been approved by the FDA to date. We get the following explanation of this increased risk of toe, foot, or leg … More
Main Navigation Menu
➤ Pharmaceutical Drug Injury Lawsuits
➤ Asbestos and Mesothelioma Claims
➤ Benzene Diseases and Cancers Claims
➤ GenX Water Contamination Cancer Cases
➤ Breast Implants Lymphoma Cancer Cases
➤ Free Case Evaluation by Lawyer Tom Lamb
➤ About the Law Offices of Thomas J. Lamb
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Collection of Articles by Our Law Firm
Please know that you can use our Quick Contact Form to tell us a bit about your case.
Recent Articles
Fournier’s Gangrene: Side Effect For Invokana, Farxiga, And Jardiance
From this August 29, 2018 Drug Safety Communication, “FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes”, we get the following details about this new safety issue for Invokana, Farxiga, Jardiance, and similar diabetes drugs: Fournier’s … More
Appellate court requires Reynolds to disclose lists linked to asbestos lawsuit
A three-judge appellate court panel in Pennsylvania ruled Thursday that R.J. Reynolds Tobacco Co. must release lists of smokers and employees who sued Lorillard Inc. related to cigarette filters that contained asbestos. Reynolds inherited the legal liability as part of its $29.25 billion purchase … More
Zoledronic acid in the management of mesothelioma – a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial
Background: Nitrogen containing bisphosphonates such as zoledronic acid (ZA) are known to contain certain anti-cancer properties. These have been investigated in the past in various cancers such as breast, prostate and colon. ZA in particular has shown promising results in pre-clinical studies. We … More
Increased Risks Of Lower-Limb Amputations For Farxiga And Jardiance
During late August a presentation at the 2018 European Society of Cardiology Congress in Munich, Germany included evidence that the SGLT-2 inhibitors Invokana, Jardiance, and Farxiga all are associated with twofold increases for lower-limb amputations when compared to GLP-1 receptor agonists … More
Tradjenta Associated With Bullous Pemphigoid Skin Disease Side Effect
Some recent medical journal articles present new findings relevant to Tradjenta-induced bullous pemphigoid (BP), which would be a skin disease side effect. Tradjenta (linagliptin), which is part of the dipeptidyl peptidase 4 (DPP-4) inhibitors class of type 2 diabetes drugs. The first medical … More